• linkedin
  • Increase Font
  • Sharebar

    MET found safe, efficacious in pregnant stone patients

    Alpha-blocker should be included in treatment discussion, study author says

     

    The study matched the treatment cohort 2:1 with a group of pregnant women with symptomatic urolithiasis who did not get tamsulosin and found no significant differences between the two groups. The mean maternal age of the study group was 28.4 (SD, 4.15) years with the mean gestational age of the child being 38.1 weeks. Six infants (22%) were born preterm. All infants were considered appropriate for gestational age, and there were no cases of spontaneous abortion, intrauterine demise, or congenital anomalies.

    Dr. Bailey responded to a question about the size of the study, saying that it was not unusual.

    "Practitioners are understandably hesitant to give medications without a proven safety record to pregnant women, which makes even retrospective studies difficult to conduct,” he said. “Many investigations of medication exposure in pregnant women start with small, retrospective studies. The sample size of this study reflects those challenges and is on par with other initial single institution investigations into medication exposure risk during pregnancy.”

    Have you read:

    Diet, urine pH may affect urinary tract bacterial growth

    Weight-loss surgery may reduce incontinence

    Study: Low-dose-rate BT outperforms EBRT boost


    Subscribe to Urology Times to get monthly news from the leading news source for urologists.

    0 Comments

    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available

    Poll